In 10% of these tumors, HER3 overexpression was identified and was significantly associated with decreased disease-specific survival. Furthermore, in tumors with normal HER1 and HER2 expression ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

A group of researchers led by Alexander Tonevitsky, Dean of the Faculty of Biology and Biotechnology at HSE University, have ...

Exclusion criteria were the following: non-overexpression of HER2 receptor; cerebral or meningeal metastasis; grade > 1 peripheral neuropathy according to NCI-CTC; severe cardiac dysfunction or ...

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results ...